120 mg LY2784544
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neoplasms, Hematologic
Conditions
Neoplasms, Hematologic
Trial Timeline
May 22, 2012 → Dec 1, 2026
NCT ID
NCT01594723About 120 mg LY2784544
120 mg LY2784544 is a phase 2 stage product being developed by Eli Lilly for Neoplasms, Hematologic. The current trial status is active. This product is registered under clinical trial identifier NCT01594723. Target conditions include Neoplasms, Hematologic.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01594723 | Phase 2 | Active |
Competing Products
20 competing products in Neoplasms, Hematologic